Navigation Links
Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
Date:12/15/2008

MONTVALE, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has dosed the first patient in a 30-patient Phase 2 clinical trial of its proprietary topical GPx-mimetic, SYI-2074, in patients with psoriasis. The trial is planned to be a 28-day multi-center, randomized, double-blind, placebo controlled study to assess the efficacy of topical SYI-2074, applied twice daily, for the treatment of chronic, mild-to-moderate plaque psoriasis in adults. The trial is being conducted in three centers in Israel.

"We are very excited to begin phase 2 clinical trials on SYI-2074 for psoriasis," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "We believe that there is immense potential to expand the scope of treatment modalities for psoriasis following this trial and look forward to reporting results in the first quarter of 2009."

About SYI-2074

Synvista's GPx mimetic program is based on the rational design of oral and topical drugs that mimic the activity of glutathione peroxidase (GPx), the only enzyme in the human body that reduces oxidized lipids.

GPx is a well validated target for drug development. Animal models have shown that elevated activity of GPx protects animals from experiencing heart attacks and atherosclerosis and reduced levels of GPx put them at risk for those diseases or complications. In humans, research suggests the risk of cardiovascular disease varies inversely with levels of GPx activity (i.e., higher levels of oxidized lipids promote the creation of oxygen free radicals and reactive oxygen species (ROS), such as H2O2, which can promote inflammation).

As noted above, a topical form of our GPx mimetic SYI-2074 is being developed for treatment of mild to moderate plaque psoriasis, an inflammatory disease highly correlated with a molecular signaling pathway that can be inhibited by SYI-2074.

About Psoriasis

Psoriasis is an immune-mediated chronic inflammatory disease usually characterized by red lesions or silvery white scales on the skin, which usually occur on the scalp, knees, elbows, the abdomen (around the navel) and the genitals. In about a quarter of the cases, psoriasis can lead to psoriatic arthritis, another inflammatory disease affecting the joints.

While the exact cause of the disease is unknown, it is believed that both genetic and hormonal factors play a role. It is also known that the TNF-alpha pathway plays a role in the progression of the disease. Other companies have successfully developed drugs that also interfere with TNF-alpha signaling, but these similar drugs are given as injections and are indicated for more severe forms of the disease. Synvista intends to differentiate SYI-2074 by developing a topical formulation of the drug for the treatment of mild-to-moderate psoriasis.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical laboratory test that identifies diabetic patients with the Haptoglobin genotype Hp2-2. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a test kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure.

For more information, please visit the Company's Web site at www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the Company's ability to obtain sufficient financial resources to continue operations, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
4. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
7. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
8. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):